Chinese | English

Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners

Linkedbio Report No.131

Having access to innovative assets without leaving home

One of Lingmed LTD missions is “Bring Innovative healthcare products to China market to improve Chinese patients’ life quality and save lives.” In order to achieve this mission, currently Lingmed support big Pharma in China to identify good innovative assets to bridge the innovation into China market. This week,Lingmed want to share with you two innovative assets.
  • Proprietary Platform enables the rational design of highly competitive nano-medicines
  • The blockbuster product candidate Nano-docetaxel has preclinical superior efficacy and tolerability as compared to docetaxel
  • Broad Applicability: can be applied for small molecules, peptides and oligonucleotides, and combinations thereof
Download the full report

Linkedbio Report No.130

Which one do you want? Red Rose or White Rose

Antibody-drug conjugate (ADC) is an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. Unlike chemotherapy, ADCs are intended to target and kill only the cancer cells and spare healthy cells. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. As the first ADCs which linked to Amanitin, LMP0847 show great anti-tumor efficacy and also prevent its high liver toxicity, which are expected to become the first-line therapy to treat cancer.
  • Antibody-drug Conjugate with excellent targeting ability and high anti-tumor efficacy than Kadcyla (Roche)
  • Low toxicity of free toxin due to low membrane permeability
  • Germany-based biotech company, focus on ADCs research
  • Kadcyla (the ADC drug from Roche) shows excellent market performance and forecasted to be 1.125b USA dollars in 2022 (EvaluatePharma)
Download the full report

If you are interested in Lingmed historical reports,You may contact us by Tel: +86 21 5386 3003 or email

Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *

©Copyright 2013 - 2017 Lingmed Limited